Efficacy and Safety of Endoscopic Intralesional Triamcinolone Injection for Benign Esophageal Strictures

Table 1

Characteristic of included randomized controlled trials.

Study	Country	Case (T/C, )	Age (T/C, y)	Intervention (T/C)		Dose	Diagnosis	Follow-up (months)
				T	C
Takahashi et al. 2015 [16]	Brazil	7/7	39 (23–64)/46 (22–65)	ED + ITI	ED + saline injection	40 mg	Corrosive stenosis	12
Altintas et al. 2004 [17]	Turkey	10/11	49 (24–69)/45 (17–76)	ED + ITI	ED	32 mg	Corrosive, surgical, postradiotherapy	>6
Ramage et al. 2005 [18]	USA	15/15	66/67	ED + ITI	ED	20 mg	Corrosive esophageal stricture	>12
Hirdes et al. 2013 [19]	Netherlands	29/31	64 ± 9/62 ± 8	ED + ITI	ED + saline injection	20 mg	Anastomotic stricture	6
Pereira-Lima et al. 2015 [20]	Brazil	10/9	56 ± 8/52 ± 15	ED + ITI	ED	40 mg	Anastomotic stricture	6
Camargo et al. 2003 [21]	Japan	16/16	70 ± 10/71 ± 7	ED + ITI	ED	>30 mg	Endoscopic surgery stricture	>16

Data were presented as mean ± standard deviation or median (range); T, treatment group; C, control group. ED, endoscopic dilation. ITI, intralesional triamcinolone injection.